3-Chloromethcathinone (3-CMC) (chemical name: 1-(3-chlorophenyl)-2-(methylamino)propan-1-one) is a synthetic cathinone that functions to inhibit reuptake of the dopamine, serotonin, and norepinephrine transporters in the central nervous system. Functionally this increases the concentration of these neurotransmitters which leads to psychostimulatory effects. Humans and animals have demonstrated clinical signs of agitation, restlessness, seizures, high blood pressure, and increased locomotor activity. The appearance of 3-CMC on the illicit drug market is similar to other designer drugs trafficked for their psychoactive effects. There are no commercial or approved medical uses for 3-CMC in the United States. Methcathinone was controlled in Schedule I of the CSA on October 15, 1993. As a positional isomer of methcathinone, 3-CMC is controlled in Schedule I of the CSA. As such, additional permanent controls will not be needed if 3-CMC is placed in Schedule II of the Convention on Psychotropic Substances, 1971.

Dipentylone (chemical name: 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one, also known as N,N-dimethylpentylone, dimethylpentylone or bk-DMBDP) is a synthetic cathinone that produces psychostimulant effects similar to cathinone. Dipentylone functions by increasing the concentration of dopamine, serotonin, and norepinephrine in the central nervous system similar to amphetamines. Anecdotal reports indicate that dipentylone produces clinical effects of insomnia, hallucinations, paranoia, and confusion. As of 2021, dipentylone was identified in 8,368 drug seizures, and was confirmed as the cause of death in at least nine fatalities in 2023. There are no commercial or approved medical uses for dipentylone in the United States. Pentylone was controlled in Schedule I of the CSA on March 4, 2016. As a positional isomer of pentylone, dipentylone is controlled in Schedule I of the CSA. As such, additional permanent controls will not be needed if dipentylone is placed in Schedule II of the Convention on Psychotropic Substances, 1971.

2-Fluorodeschloroketamine (chemical name: 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one), fluoroketamine, or 2-FDCK) is an arylcyclohexylamine that is related to ketamine and phencyclidine (PCP). 2-FDCK is thought to function as an N-methyl-D-aspartate receptor antagonist and produce effects similar to other dissociative anesthetics (*e.g.,* ketamine). According to anecdotal reports, these effects include dissociation, hallucination, confusion, agitation, stimulation, and tachycardia and hypertension. Studies in animals indicate that 2-FDCK was self-administered (*i.e.,* produced reinforcing effects) and produced a drug cue similar to that of ketamine. As a result, animal data suggests that 2-FDCK has an abuse potential similar to ketamine. 2-FDCK has not been detected in law enforcement seizures, or in toxicology screens in the United States. There are no commercial or approved medical uses for 2-FDCK, and it is not a controlled substance under the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if 2-FDCK is controlled under Schedule II of the Convention on Psychotropic Substances, 1971.

Bromazolam (chemical name: 8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a triazolobenzodiazepine that functions as a positive allosteric modulator of γ-aminobutyric acid A ($GABA_A$) channels thereby decreasing neuronal activity. Similar to other benzodiazepines, such as alprazolam, it produces sedative and anxiolytic effects typically taken after oral administration or through injection. Unconfirmed anecdotal reports indicate that it can also produce hypnotic, muscle relaxant, and euphoric effects as well as physical dependence demonstrated through a withdrawal syndrome. Since 2021, bromazolam has been detected in 637 law enforcement seizures and has been implicated in 53 fatalities. There are no commercial or approved medical uses for bromazolam in the United States, and it is not a controlled substance under the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if bromazolam is controlled under Schedule IV of the Convention on Psychotropic Substances, 1971.

FDA, on behalf of the Secretary of HHS, invites interested persons to submit comments on the notifications from the United Nations concerning these drug substances. FDA, in cooperation with the National Institute on Drug Abuse, will consider the comments on behalf of HHS in evaluating the WHO scheduling recommendations. Then, under section 201(d)(2)(B) of the CSA, HHS will recommend to the Secretary of State what position the United States should take when voting on the recommendations for control of substances under the 1971 Convention at the CND meeting in March 2024.

Comments regarding the WHO recommendations for control of butonitazene under the 1961 Single Convention will also be forwarded to the relevant Agencies for consideration in developing the U.S. position regarding narcotic substances at the CND meeting.

Dated: February 5, 2024.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2024–02573 Filed 2–7–24; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Technologies for Global Health.

Date: February 13, 2024.

Time: 9:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W238, Rockville, Maryland 20850 (Virtual Meeting).

Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W238, Rockville, Maryland 20850, 240–276–6371, *decluej@mail.nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 5, 2024.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–02593 Filed 2–7–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of General Medical Sciences Special Emphasis Panel, Review of PRAT and K99/R00 MOCSAC Applications. March 04, 2024, 10:30 a.m. to March 05, 2024, 06:30 p.m., National Institute of General Medical Sciences, Natcher Building, 45 Center Drive, Bethesda, Maryland, 20892 which was published in the **Federal Register** on January 19, 2024, FR. Doc. 2024–00950, 89 FR 3671.

This notice is being amended to change the name of the panel from Review of PRAT and K99/R00 MOCSAC Applications to the Review of PRAT and K99/R00 MOSAIC Applications. The meeting date, time, and location will stay the same. The meeting is closed to the public.

Dated: February 2, 2024.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–02582 Filed 2–7–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; SBIR contract topic 010.

Date: March 15, 2024.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Nijaguna Prasad, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, 7201 Wisconsin Avenue, Gateway Bldg., Suite 2W200, (301) 496–9667, *prasadnb@nia.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: February 2, 2024.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–02583 Filed 2–7–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Targeted Cancer Therapies.

Date: March 4, 2024.

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lawrence Ka-Yun Ng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6152, MSC 7804, Bethesda, MD 20892, 301–435–1719, *ngkl@csr.nih.gov.*

Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Chemical Synthesis and Biosynthesis Study Section.

Date: March 6–7, 2024.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Shan Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–4390, *shan.wang@nih.gov.*

Name of Committee: Emerging Technologies and Training Neurosciences Integrated Review Group; Bioengineering of Neuroscience, Vision and Low Vision Technologies Study Section.

Date: March 7–8, 2024.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Tina Tze-Tsang Tang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Suite 3030, Bethesda, MD 20817, (301) 435–4436, *tangt@mail.nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Health Services and Systems.

Date: March 8, 2024.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Mary Kate Baker, DRPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–5117, *katie.baker2@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Computational, Modeling, and Biodata Management.

Date: March 8, 2024.

Time: 10:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 6188, MSC 7804, Bethesda, MD 20892, 301–435–1267, *belangerm@csr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 2, 2024.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–02581 Filed 2–7–24; 8:45 am]

BILLING CODE 4140–01–P